



**BROUGHT TO YOU BY**  
**YTP CHAIRPERSON**  
**Dr. Neharika M Bora**  
 MD(obgyn), DRM Germ City  
 Rainbow IVF, Agr




**Author - Dr. Shehla Jamal**  
 Assistant Professor SMS & R,  
 Sharda University  
 Noida

## " YTP UPDATE 2020"

### Thalassemia in Pregnancy Update

Thalassemia is known to be associated with an increased risk to both mother and the fetus. The pertinent issues surrounding thalassemia in pregnancy is cardiomyopathy in the mother due to iron overload and the increased risk of fetal growth restriction. Hemoglobinopathies are among the most common inherited diseases: approximately 7% of the global population is a carrier. It is a group of Autosomal Recessive inherited disease and worldwide more than 70000 babies are born each year. In India around 15000 newborns are diagnosed with this disorders and the number of undiagnosed cases remains unknown.



#### Presentation :

The clinical picture varies with the type of disorder inherited, from transfusion dependent in Thalassemia major to mild to moderate anemia in carrier.

Specific considerations in pregnancy are:

1. Anemia in carriers, (low, normal, or slightly subnormal hemoglobin levels, slightly low mean cell hemoglobin, low mean cell volume, low alpha-globin chain ratio on biosynthesis, HbA<sub>2</sub> < 3.5%) are observed
2. FGR
3. Endocrinopathies (specifically with major and intermediate variety)
4. Liver dysfunction
5. Cardiac complications
6. Thromboembolic events
7. Preterm birth
8. Risk of CMV, Pneumococcus in splenectomised patients

## Antenatal work up :

Every Obstetrician should aim for screening each pregnancy for Thalassemia. Important points not to be missed are:

- Detailed history- consanguinity, repeated blood transfusions
- Complete blood counts, use MCH, MCV for screening
- Usage of Mentzer's/ Shiney & L's indices etc for screening in 1<sup>st</sup> pregnancies with thalassaemia
- Assess Cardiac function by ECG, 2D Echo, liver functions, diabetes using OGTT and Fructosamine levels, in known case of Thalassemia
- Review drug history, especially for chelating agents, in TM.
- Fetal Surveillance
- ABO and Rh status
- Hep B & C status
- HPLC / Hb Electrophoresis for diagnosis
- Genetic counselling in confirmed cases

These patients are at increased risk of Cholelithiasis, hypertensive disorders, abortion, UTI, nephrolithiasis, Vit D deficiency and Osteoporosis.

## Pathophysiology:


### Due to the disorder :

The basic defect in the thalassaemia syndromes is reduced globin chain synthesis with the resultant red cells having inadequate haemoglobin content. The pathophysiology of thalassaemia syndromes is characterised by extravascular haemolysis due to the release into the peripheral circulation of damaged red blood cells and erythroid precursors because of a high degree of ineffective erythropoiesis.

This leads to thalassaemic tissue hypoxia and its sequelae.

### Due to treatment :

Repeated transfusions lead to iron overload and its tissue deposition, especially in cardiac Muscles, liver and anterior pituitary. Chelation therapy poses risk of osteoporosis and Vitamin D deficiency. And if preconception counselling is not provided, chelation agents can turn out to be teratogenic also.



## Management :

Multidisciplinary team involving haematologist, cardiologist along with Obstetrician should manage such case.

Women should be advised to modify their lifestyle and diet, avoid smoking and alcohol, and start taking folic acid (5mg/day), calcium, and vitamin D in required doses.

Frequent antenatal visits should be explained. Women with thalassaemia should be reviewed monthly until 28 weeks of gestation and every two weeks thereafter.

Iron chelators should be reviewed and deferasirox and deferriprone ideally discontinued three months before conception. In vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI) with pre-implantation genetic diagnosis (PGD) should be considered in the presence of haemoglobinopathies in both partners so that homozygous or compound heterozygous pregnancy can be avoided.

Vaccination for Hep B ideally pre conception should be advised..

Low dose Aspirin, 75 mg should be prescribed to splenectomised patients. A target Hb of 10gm% should be maintained.

Thrombophylaxis might be essential during pregnancy and the postpartum period in cases of nontransfused Transfusion independent, splenectomy, those with a serum platelet count above  $600 \times 10^9/L$  or a history of recurrent abortions.

#### **Fetal Surveillance :**

In addition to first-trimester (11th–14th weeks) and second trimester (18th–21st weeks) scans, serial fetal biometry scans should be performed monthly after the 24th gestation week, focusing on possible growth restriction which can result due to chronic maternal anemia and other nutrition elements depletion.

### **Delivery considerations :**

Time and mode of delivery should be individualized for thalassemia per se, as an uncomplicated disease course should not be considered a direct indication for CS. In case of CS, epidural anesthesia is preferable compared to general anesthesia. Active management of the third stage of delivery is recommended, as this intervention reduces blood loss.

Intravenous DFO – 2 g over 24 hours – is recommended for the duration of labor.

In the postpartum period, low-molecular-weight heparin prophylaxis should be administered in hospital, followed by a 7-day postdischarge regimen after vaginal delivery or a 6-week regimen after CS. Breast feeding should be encouraged and postpartum chelation using DFO seems to be safe, as DFO is not orally absorbed. Calcium and vitamin D supplements should be continued during breast-feeding, but bisphosphonates should be resumed after cessation of breast-feeding.

### **References**

1. Pregnancy in women with thalassemia: challenges and solutions  
George Petrakos, Panagiotis Andriopoulos, Maria Tsironi  
Int J Womens Health. 2016; 8: 441–451. Published online 2016 Sep 8. doi: 10.2147/IJWH.S89308  
PMCID: PMC5019437
2. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010;115:4331–4336
3. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood. 2002;99:36–43.
4. Xu TT, Zhou F, Deng CY, et al. Low-dose aspirin for preventing preeclampsia and its complications: meta-analysis. J Clin Hypertens (Greenwich) 2015;17:567–573. [PubMed] [Google Scholar]
5. Royal College of Obstetricians and Gynecologists. Blood Transfusions in Obstetrics. Green-top Guideline No. 47. London: RCOG; 2007.
6. Royal College of Obstetricians and Gynecologists. Management of Beta Thalassemia in pregnancy. GTG no. 66, March 2016.